probenecid has been researched along with AIDS-Related Opportunistic Infections in 12 studies
Probenecid: The prototypical uricosuric agent. It inhibits the renal excretion of organic anions and reduces tubular reabsorption of urate. Probenecid has also been used to treat patients with renal impairment, and, because it reduces the renal tubular excretion of other drugs, has been used as an adjunct to antibacterial therapy.
probenecid : A sulfonamide in which the nitrogen of 4-sulfamoylbenzoic acid is substituted with two propyl groups.
AIDS-Related Opportunistic Infections: Opportunistic infections found in patients who test positive for human immunodeficiency virus (HIV). The most common include PNEUMOCYSTIS PNEUMONIA, Kaposi's sarcoma, cryptosporidiosis, herpes simplex, toxoplasmosis, cryptococcosis, and infections with Mycobacterium avium complex, Microsporidium, and Cytomegalovirus.
| Excerpt | Relevance | Reference |
|---|---|---|
| " Average key pharmacokinetic parameters (Cmax, tmax, lambda z, AUC0-infinity, Vss, CL, CLR, fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data." | 6.71 | Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. ( Duncan, BA; Ingrosso, A; Mucci, M; Nickens, DJ; Rodríguez, CA; Wolf, DL, 2003) |
| "5 mg/kg with concomitant oral probenecid, saline prehydration, extended dosing intervals, and drug interruption for proteinuria (19 patients)." | 5.08 | (S)-1-[3-hydroxy-2-(phosphonylmethoxy)propyl]cytosine (cidofovir): results of a phase I/II study of a novel antiviral nucleotide analogue. ( Cundy, K; Drew, WL; Fisher, PE; Flaherty, J; Glutzer, E; Hannigan, J; James, C; Lalezari, JP; Martin, JC; Miner, D, 1995) |
| "The authors characterize and analyze the incidence of a previously reported mild anterior nongranulomatous uveitis associated with intravitreal injections of (S)-1-(3-hydroxy-2-phosphonylmethoxypropyl)cytosine (HPMPC), also termed cidofovir (Vistide, Gilead Sciences, Foster City, CA)." | 5.08 | Anterior nongranulomatous uveitis after intravitreal HPMPC (cidofovir) for the treatment of cytomegalovirus retinitis. Analysis and prevention. ( Arevalo, JF; Chavez-de la Paz, E; De Clercq, E; Freeman, WR; Kirsch, LS; Munguia, D; Rahhal, FM, 1997) |
| " Average key pharmacokinetic parameters (Cmax, tmax, lambda z, AUC0-infinity, Vss, CL, CLR, fe, ER) for RDP differed by less than 17% from SDP and were consistent with previously reported SDP data." | 2.71 | Pharmacokinetics and renal effects of cidofovir with a reduced dose of probenecid in HIV-infected patients with cytomegalovirus retinitis. ( Duncan, BA; Ingrosso, A; Mucci, M; Nickens, DJ; Rodríguez, CA; Wolf, DL, 2003) |
| " Dose-dependent asymptomatic proteinuria (39%) and serum creatinine elevation (24%) were the most common adverse events thought to be related to cidofovir." | 2.69 | Randomized, controlled study of the safety and efficacy of intravenous cidofovir for the treatment of relapsing cytomegalovirus retinitis in patients with AIDS. ( Hardy, WD; Holland, GN; Ives, DV; Jaffe, HS; Johnson, M; Kemper, CA; Kramer, F; Kuppermann, BD; Lalezari, JP; Lewis, RA; McKinley, GF; Nelson, R; Northfelt, DW; Ruby, AE; Simon, GL; Stagg, RJ; Weinberg, DV; Wolitz, RA; Youle, M, 1998) |
| "Eligible patients with acquired immune deficiency syndrome had active CMV retinitis in at least one eye and no evidence of extraocular CMV disease." | 2.68 | Intravitreal cidofovir (HPMPC) treatment of cytomegalovirus retinitis in patients with acquired immune deficiency syndrome. ( Arevalo, JF; Chavez de la Paz, E; de Clercq, E; Freeman, WR; Kirsch, LS; Munguia, D, 1995) |
| "Recommendations for treatment of syphilis remain the same for patients with and without HIV." | 2.42 | Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management. ( Augenbraun, M; Zellan, J, 2004) |
| " In addition, four treatment modifications were indicated to reduce the incidence of cidofovir-related nephrotoxicity: (a) dose reduction or interruption for changes in renal function; (b) concomitant administration of probenecid; (c) administration of 1 L of normal saline 1 h before infusion of cidofovir; and (d) extension of the dosing interval." | 2.40 | Cidofovir: a new therapy for cytomegalovirus retinitis. ( Lalezari, JP, 1997) |
| "0 mg/kg of body weight and declined biexponentially with an overall mean +/- standard deviation terminal half-life of 2." | 1.29 | Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients. ( Cundy, KC; Fisher, PE; Flaherty, J; Hitchcock, MJ; Jaffe, HS; Lalezari, JP; Lietman, PS; Petty, BG; Polis, MA; Wachsman, M, 1995) |
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 9 (75.00) | 18.2507 |
| 2000's | 3 (25.00) | 29.6817 |
| 2010's | 0 (0.00) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Wolf, DL | 1 |
| Rodríguez, CA | 1 |
| Mucci, M | 1 |
| Ingrosso, A | 1 |
| Duncan, BA | 1 |
| Nickens, DJ | 1 |
| Zellan, J | 1 |
| Augenbraun, M | 1 |
| Cundy, KC | 1 |
| Petty, BG | 1 |
| Flaherty, J | 2 |
| Fisher, PE | 2 |
| Polis, MA | 1 |
| Wachsman, M | 1 |
| Lietman, PS | 1 |
| Lalezari, JP | 4 |
| Hitchcock, MJ | 1 |
| Jaffe, HS | 2 |
| Drew, WL | 1 |
| Glutzer, E | 1 |
| James, C | 1 |
| Miner, D | 1 |
| Cundy, K | 1 |
| Hannigan, J | 1 |
| Martin, JC | 1 |
| Kirsch, LS | 2 |
| Arevalo, JF | 2 |
| Chavez de la Paz, E | 1 |
| Munguia, D | 2 |
| de Clercq, E | 2 |
| Freeman, WR | 2 |
| Chavez-de la Paz, E | 1 |
| Rahhal, FM | 1 |
| Holland, GN | 1 |
| Kramer, F | 1 |
| McKinley, GF | 1 |
| Kemper, CA | 1 |
| Ives, DV | 1 |
| Nelson, R | 1 |
| Hardy, WD | 1 |
| Kuppermann, BD | 1 |
| Northfelt, DW | 1 |
| Youle, M | 1 |
| Johnson, M | 1 |
| Lewis, RA | 1 |
| Weinberg, DV | 1 |
| Simon, GL | 1 |
| Wolitz, RA | 1 |
| Ruby, AE | 1 |
| Stagg, RJ | 1 |
| Gupta, S | 1 |
| Aggarwal, S | 1 |
| Nakamura, S | 1 |
| Scott, RA | 1 |
| Pavesio, C | 1 |
| Bowers, M | 1 |
| Trial | Phase | Enrollment | Study Type | Start Date | Status | ||
|---|---|---|---|---|---|---|---|
| Studies of the Ocular Complications of AIDS (SOCA)--HPMPC Peripheral CMV Retinitis Trial (HPCRT)[NCT00000142] | Phase 2/Phase 3 | 64 participants (Actual) | Interventional | 1994-04-30 | Completed | ||
| HPMPC (Cidofovir) Peripheral CMV Retinitis Trial Protocol[NCT00000799] | 100 participants | Interventional | Completed | ||||
| [information is prepared from clinicaltrials.gov, extracted Sep-2024] | |||||||
(NCT00000142)
Timeframe: All patients enrolled will be followed until a common study closing date
| Intervention | participants (Number) | ||
|---|---|---|---|
| mortality | progression | va loss of 15 letters | |
| Cidofovir (High Dose) | 3 | 5 | 2 |
| Cidofovir (Low Dose) | 7 | 17 | 6 |
| Treatment Deferral | 6 | 20 | 4 |
2 reviews available for probenecid and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Syphilis in the HIV-infected patient: an update on epidemiology, diagnosis, and management.
Topics: Administration, Oral; AIDS-Related Opportunistic Infections; Amoxicillin; Clinical Trials as Topic; | 2004 |
Cidofovir: a new therapy for cytomegalovirus retinitis.
Topics: AIDS-Related Opportunistic Infections; Animals; Antiviral Agents; Cidofovir; Clinical Trials, Phase | 1997 |
6 trials available for probenecid and AIDS-Related Opportunistic Infections
4 other studies available for probenecid and AIDS-Related Opportunistic Infections
| Article | Year |
|---|---|
Clinical pharmacokinetics of cidofovir in human immunodeficiency virus-infected patients.
Topics: Adult; AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infection | 1995 |
A possible role of multidrug resistance-associated protein (MRP) in basic fibroblast growth factor secretion by AIDS-associated Kaposi's sarcoma cells: a survival molecule?
Topics: AIDS-Related Opportunistic Infections; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Mem | 1998 |
Ocular side-effects from systemic HPMPC (Cidofovir) for a non-ocular cytomegalovirus infection.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Infections; Cyto | 2000 |
Cidofovir.
Topics: AIDS-Related Opportunistic Infections; Antiviral Agents; Cidofovir; Cytomegalovirus Retinitis; Cytos | 1998 |